Advances in hepatitis C therapy: What is the current state-what come's next?

查看全文 作　　者：Steffen [1]Zopf;Andreas E [1]Kremer;Markus F [1]Neurath;Juergen [1]Siebler

机构地区：[1]Medical Department 1 University of Erlangen Nuremberg

出　　处：《World Journal of Hepatology》索引2016年第8卷第3期,共9页

摘　　要：Chronic hepatitis C virus(HCV) infection affects 80-160 million people worldwide and is one of the leading causes of chronic liver disease.It is only a few years ago that standard treatment regimes were based on pegylated interferon alpha and ribavirin.However,treatment of HCV has undergone a revolutionary change in recent years.The admission of the nucleotide polymerase inhibitor Sofosbuvir enabled an interferon-free regimen with direct antiviral agents(DAA).Meanwhile seven DAAs are available and can be applied in several combinations for 8 to 24 wk depending on HCV genotype and patient characteristics such as cirrhosis and chronic renal failure.High rates of sustained virological response(SVR) rates can be achieved with these novel drugs.Even in difficult to treat populations such as patients with liver cirrhosis,HCV-human immunodeficiency virus co-infections,after liver transplantion,or with chronic kidney disease comparable high rates of SVR can be achieved.The anticipated 2nd generation DAAs are strikingly effective in patients so far classified as difficult to treat including decompensated liver cirrhosis or posttransplant patients.These 2nd generations DAAs will have higher resistance barriers,higher antiviral effects and a pan-genotypic spectrum.This review highlights the current state of the art of antiviral treatment in hepatitis Cand gives an outlook for upcoming therapies. 关键词：hepatitis C virus direct ANTIVIRAL agents SUSTAINED virological response liver transplantation RENAL IMPAIRMENT CIRRHOSIS

相关文献

参考文献（53）
引证文献（7）
耦合文献（0）

参考文献(53)

引证文献(7)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Advances in hepatitis C therapy: What is the current state-what come's next?

参考文献(53)

引证文献(7)

用户提示